POTENTIAL TARGETS FROM HUMAN (RESULTS FROM SUB-STRUCTURAL SIMILARITY SEARCHES)
1) User may click on the DrReposER ID (the second column) to get information on the binding sites and drug molecule.
2) Click View (the second last column) to view matched residues and superposition in the NGL viewer (upper right part).
3) User may also click on the Dock (the last column) to get script for molecular docking in UCSF Chimera through AutoDock Vina.

DrReposER ID / Desc. Hit
PDBID		 Hit
Macromolecule		 Res.
Matches		 Interface HETATM RMSD Seq.
Identity (%)		 View Dock
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4AMJ_A_CVDA1359_1
(BETA-1 ADRENERGIC
RECEPTOR)		3egi TRIMETHYLGUANOSINE
SYNTHASE HOMOLOG
(Homo
sapiens)		5 / 12VAL A 685
PHE A 761
PHE A 708
ASN A 704
TYR A 841
None
1.50A20.00
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4AMJ_A_CVDA1359_1
(BETA-1 ADRENERGIC
RECEPTOR)		3pbl D(3) DOPAMINE
RECEPTOR, LYSOZYME
CHIMERA
(Escherichia
virus
T4;
Homo
sapiens)		5 / 12ASP A 110
VAL A 111
SER A 192
PHE A 346
TYR A 373
ETQ  A1200 (-3.5A)
ETQ  A1200 (-3.4A)
ETQ  A1200 (-3.3A)
ETQ  A1200 ( 4.5A)
ETQ  A1200 (-4.4A)
1.19A29.71
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4AMJ_A_CVDA1359_1
(BETA-1 ADRENERGIC
RECEPTOR)		3pbl D(3) DOPAMINE
RECEPTOR, LYSOZYME
CHIMERA
(Escherichia
virus
T4;
Homo
sapiens)		8 / 12ASP A 110
VAL A 111
SER A 192
SER A 196
TRP A 342
PHE A 345
PHE A 346
TYR A 373
ETQ  A1200 (-3.5A)
ETQ  A1200 (-3.4A)
ETQ  A1200 (-3.3A)
ETQ  A1200 ( 4.6A)
None
ETQ  A1200 (-4.4A)
ETQ  A1200 ( 4.5A)
ETQ  A1200 (-4.4A)
0.71A29.71
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4AMJ_A_CVDA1359_1
(BETA-1 ADRENERGIC
RECEPTOR)		3pbl D(3) DOPAMINE
RECEPTOR, LYSOZYME
CHIMERA
(Escherichia
virus
T4;
Homo
sapiens)		5 / 12ASP A 110
VAL A 111
SER A 196
PHE A 345
PHE A 346
ETQ  A1200 (-3.5A)
ETQ  A1200 (-3.4A)
ETQ  A1200 ( 4.6A)
ETQ  A1200 (-4.4A)
ETQ  A1200 ( 4.5A)
1.47A29.71
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4AMJ_A_CVDA1359_1
(BETA-1 ADRENERGIC
RECEPTOR)		3pds FUSION PROTEIN
BETA-2 ADRENERGIC
RECEPTOR/LYSOZYME
(Escherichia
virus
T4;
Homo
sapiens)		7 / 12TRP A 109
ASP A 113
VAL A 114
SER A 207
PHE A 289
ASN A 312
TYR A 316
None
ERC  A1201 (-3.7A)
ERC  A1201 (-3.8A)
ERC  A1201 (-2.7A)
ERC  A1201 (-4.5A)
ERC  A1201 (-3.0A)
None
1.16A42.70
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4AMJ_A_CVDA1359_1
(BETA-1 ADRENERGIC
RECEPTOR)		3pds FUSION PROTEIN
BETA-2 ADRENERGIC
RECEPTOR/LYSOZYME
(Escherichia
virus
T4;
Homo
sapiens)		11 / 12TRP A 109
ASP A 113
VAL A 114
VAL A 117
SER A 203
SER A 207
TRP A 286
PHE A 289
PHE A 290
ASN A 293
TYR A 316
None
ERC  A1201 (-3.7A)
ERC  A1201 (-3.8A)
None
ERC  A1201 (-2.8A)
ERC  A1201 (-2.7A)
None
ERC  A1201 (-4.5A)
ERC  A1201 (-4.8A)
ERC  A1201 (-3.5A)
None
0.71A42.70
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4AMJ_A_CVDA1359_1
(BETA-1 ADRENERGIC
RECEPTOR)		3pds FUSION PROTEIN
BETA-2 ADRENERGIC
RECEPTOR/LYSOZYME
(Escherichia
virus
T4;
Homo
sapiens)		11 / 12TRP A 109
ASP A 113
VAL A 114
VAL A 117
SER A 203
TRP A 286
PHE A 289
PHE A 290
ASN A 293
ASN A 312
TYR A 316
None
ERC  A1201 (-3.7A)
ERC  A1201 (-3.8A)
None
ERC  A1201 (-2.8A)
None
ERC  A1201 (-4.5A)
ERC  A1201 (-4.8A)
ERC  A1201 (-3.5A)
ERC  A1201 (-3.0A)
None
0.68A42.70
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4AMJ_A_CVDA1359_1
(BETA-1 ADRENERGIC
RECEPTOR)		3pds FUSION PROTEIN
BETA-2 ADRENERGIC
RECEPTOR/LYSOZYME
(Escherichia
virus
T4;
Homo
sapiens)		5 / 12TRP A 109
ASP A 113
VAL A 117
SER A 204
TYR A 316
None
ERC  A1201 (-3.7A)
None
ERC  A1201 ( 4.1A)
None
1.33A42.70
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4AMJ_A_CVDA1359_1
(BETA-1 ADRENERGIC
RECEPTOR)		3pds FUSION PROTEIN
BETA-2 ADRENERGIC
RECEPTOR/LYSOZYME
(Escherichia
virus
T4;
Homo
sapiens)		5 / 12VAL A 114
PHE A 289
ASN A 293
ASN A 312
TYR A 316
ERC  A1201 (-3.8A)
ERC  A1201 (-4.5A)
ERC  A1201 (-3.5A)
ERC  A1201 (-3.0A)
None
1.21A42.70
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4AMJ_A_CVDA1359_1
(BETA-1 ADRENERGIC
RECEPTOR)		3rze HISTAMINE H1
RECEPTOR, LYSOZYME
CHIMERA
(Escherichia
virus
T4;
Homo
sapiens)		5 / 12TRP A 103
ASP A 107
TRP A 428
PHE A 432
TYR A 458
None
5EH  A1200 ( 2.6A)
5EH  A1200 ( 3.4A)
5EH  A1200 ( 4.3A)
5EH  A1200 ( 4.4A)
0.66A26.75
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4AMJ_A_CVDA1359_1
(BETA-1 ADRENERGIC
RECEPTOR)		4gbr BETA-2 ADRENERGIC
RECEPTOR
(Homo
sapiens)		12 / 12TRP A 109
ASP A 113
VAL A 114
VAL A 117
SER A 203
SER A 207
TRP A 258
PHE A 261
PHE A 262
ASN A 265
ASN A 284
TYR A 288
None
CAU  A 500 (-3.0A)
CAU  A 500 (-3.5A)
CAU  A 500 (-4.2A)
CAU  A 500 (-3.3A)
CAU  A 500 (-4.1A)
None
CAU  A 500 (-4.2A)
CAU  A 500 (-4.6A)
CAU  A 500 (-3.4A)
CAU  A 500 (-3.3A)
CAU  A 500 (-4.6A)
0.49A58.02
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4AMJ_A_CVDA1359_1
(BETA-1 ADRENERGIC
RECEPTOR)		4ib4 CHIMERA PROTEIN OF
HUMAN
5-HYDROXYTRYPTAMINE
RECEPTOR 2B AND E.
COLI SOLUBLE
CYTOCHROME B562
(Escherichia
coli;
Homo
sapiens)		5 / 12TRP A 131
ASP A 135
SER A 222
TRP A 337
TYR A 370
None
ERM  A2001 (-3.2A)
ERM  A2001 ( 4.6A)
None
ERM  A2001 ( 4.8A)
1.37A28.44
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4AMJ_A_CVDA1359_1
(BETA-1 ADRENERGIC
RECEPTOR)		4ib4 CHIMERA PROTEIN OF
HUMAN
5-HYDROXYTRYPTAMINE
RECEPTOR 2B AND E.
COLI SOLUBLE
CYTOCHROME B562
(Escherichia
coli;
Homo
sapiens)		8 / 12TRP A 131
ASP A 135
VAL A 136
TRP A 337
PHE A 340
PHE A 341
ASN A 344
TYR A 370
None
ERM  A2001 (-3.2A)
ERM  A2001 (-3.8A)
None
ERM  A2001 (-4.3A)
None
ERM  A2001 (-4.3A)
ERM  A2001 ( 4.8A)
0.61A28.44
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4AMJ_A_CVDA1359_1
(BETA-1 ADRENERGIC
RECEPTOR)		4lde LYSOZYME, BETA-2
ADRENERGIC RECEPTOR
(Escherichia
virus
T4;
Homo
sapiens)		6 / 12TRP A1109
ASP A1113
VAL A1114
SER A1203
PHE A1290
TYR A1316
None
P0G  A1401 (-2.9A)
P0G  A1401 (-3.7A)
P0G  A1401 (-2.9A)
P0G  A1401 ( 4.9A)
None
1.39A42.33
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4AMJ_A_CVDA1359_1
(BETA-1 ADRENERGIC
RECEPTOR)		4lde LYSOZYME, BETA-2
ADRENERGIC RECEPTOR
(Escherichia
virus
T4;
Homo
sapiens)		9 / 12TRP A1109
ASP A1113
VAL A1114
SER A1203
TRP A1286
PHE A1289
PHE A1290
ASN A1312
TYR A1316
None
P0G  A1401 (-2.9A)
P0G  A1401 (-3.7A)
P0G  A1401 (-2.9A)
None
P0G  A1401 ( 4.7A)
P0G  A1401 ( 4.9A)
P0G  A1401 (-2.9A)
None
0.75A42.33
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4AMJ_A_CVDA1359_1
(BETA-1 ADRENERGIC
RECEPTOR)		4lde LYSOZYME, BETA-2
ADRENERGIC RECEPTOR
(Escherichia
virus
T4;
Homo
sapiens)		9 / 12TRP A1109
ASP A1113
VAL A1114
TRP A1286
PHE A1289
PHE A1290
ASN A1293
ASN A1312
TYR A1316
None
P0G  A1401 (-2.9A)
P0G  A1401 (-3.7A)
None
P0G  A1401 ( 4.7A)
P0G  A1401 ( 4.9A)
P0G  A1401 (-3.0A)
P0G  A1401 (-2.9A)
None
0.56A42.33
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4AMJ_A_CVDA1359_1
(BETA-1 ADRENERGIC
RECEPTOR)		4lde LYSOZYME, BETA-2
ADRENERGIC RECEPTOR
(Escherichia
virus
T4;
Homo
sapiens)		8 / 12TRP A1109
ASP A1113
VAL A1114
VAL A1117
SER A1203
SER A1207
PHE A1289
PHE A1290
None
P0G  A1401 (-2.9A)
P0G  A1401 (-3.7A)
P0G  A1401 ( 4.4A)
P0G  A1401 (-2.9A)
P0G  A1401 (-2.8A)
P0G  A1401 ( 4.7A)
P0G  A1401 ( 4.9A)
0.86A42.33
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4AMJ_A_CVDA1359_1
(BETA-1 ADRENERGIC
RECEPTOR)		4lde LYSOZYME, BETA-2
ADRENERGIC RECEPTOR
(Escherichia
virus
T4;
Homo
sapiens)		9 / 12TRP A1109
ASP A1113
VAL A1114
VAL A1117
SER A1203
TRP A1286
PHE A1289
PHE A1290
ASN A1312
None
P0G  A1401 (-2.9A)
P0G  A1401 (-3.7A)
P0G  A1401 ( 4.4A)
P0G  A1401 (-2.9A)
None
P0G  A1401 ( 4.7A)
P0G  A1401 ( 4.9A)
P0G  A1401 (-2.9A)
0.81A42.33
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4AMJ_A_CVDA1359_1
(BETA-1 ADRENERGIC
RECEPTOR)		4lde LYSOZYME, BETA-2
ADRENERGIC RECEPTOR
(Escherichia
virus
T4;
Homo
sapiens)		8 / 12TRP A1109
ASP A1113
VAL A1114
VAL A1117
SER A1207
PHE A1289
PHE A1290
ASN A1293
None
P0G  A1401 (-2.9A)
P0G  A1401 (-3.7A)
P0G  A1401 ( 4.4A)
P0G  A1401 (-2.8A)
P0G  A1401 ( 4.7A)
P0G  A1401 ( 4.9A)
P0G  A1401 (-3.0A)
0.75A42.33
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4AMJ_A_CVDA1359_1
(BETA-1 ADRENERGIC
RECEPTOR)		4lde LYSOZYME, BETA-2
ADRENERGIC RECEPTOR
(Escherichia
virus
T4;
Homo
sapiens)		9 / 12TRP A1109
ASP A1113
VAL A1114
VAL A1117
TRP A1286
PHE A1289
PHE A1290
ASN A1293
ASN A1312
None
P0G  A1401 (-2.9A)
P0G  A1401 (-3.7A)
P0G  A1401 ( 4.4A)
None
P0G  A1401 ( 4.7A)
P0G  A1401 ( 4.9A)
P0G  A1401 (-3.0A)
P0G  A1401 (-2.9A)
0.64A42.33
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4AMJ_A_CVDA1359_1
(BETA-1 ADRENERGIC
RECEPTOR)		4lde LYSOZYME, BETA-2
ADRENERGIC RECEPTOR
(Escherichia
virus
T4;
Homo
sapiens)		5 / 12VAL A1114
PHE A1289
ASN A1293
ASN A1312
TYR A1316
P0G  A1401 (-3.7A)
P0G  A1401 ( 4.7A)
P0G  A1401 (-3.0A)
P0G  A1401 (-2.9A)
None
1.36A42.33
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4AMJ_A_CVDA1359_1
(BETA-1 ADRENERGIC
RECEPTOR)		5v54 5-HYDROXYTRYPTAMINE
RECEPTOR 1B,OB-1
FUSED 5-HT1B
RECEPTOR,5-HYDROXYTR
YPTAMINE RECEPTOR 1B
(Homo
sapiens;
Spodoptera
frugiperda)		6 / 12TRP A 125
ASP A 129
SER A 212
PHE A 330
PHE A 331
TYR A 359
None
89F  A1201 (-3.3A)
89F  A1201 ( 3.8A)
89F  A1201 (-4.1A)
89F  A1201 (-4.6A)
None
1.31A14.48
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4AMJ_A_CVDA1359_1
(BETA-1 ADRENERGIC
RECEPTOR)		5v54 5-HYDROXYTRYPTAMINE
RECEPTOR 1B,OB-1
FUSED 5-HT1B
RECEPTOR,5-HYDROXYTR
YPTAMINE RECEPTOR 1B
(Homo
sapiens;
Spodoptera
frugiperda)		7 / 12TRP A 125
ASP A 129
SER A 212
TRP A 327
PHE A 330
PHE A 331
TYR A 359
None
89F  A1201 (-3.3A)
89F  A1201 ( 3.8A)
89F  A1201 (-3.6A)
89F  A1201 (-4.1A)
89F  A1201 (-4.6A)
None
0.80A14.48
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4AMJ_A_CVDA1359_1
(BETA-1 ADRENERGIC
RECEPTOR)		5wiv D(4) DOPAMINE
RECEPTOR, SOLUBLE
CYTOCHROME B562
CHIMERA
(Escherichia
coli;
Homo
sapiens)		5 / 12ASP A 115
VAL A 116
SER A 196
PHE A 411
TYR A 438
AQD  A1201 (-3.3A)
AQD  A1201 ( 3.9A)
AQD  A1201 (-2.8A)
AQD  A1201 (-4.6A)
None
1.20A32.39
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4AMJ_A_CVDA1359_1
(BETA-1 ADRENERGIC
RECEPTOR)		5wiv D(4) DOPAMINE
RECEPTOR, SOLUBLE
CYTOCHROME B562
CHIMERA
(Escherichia
coli;
Homo
sapiens)		8 / 12ASP A 115
VAL A 116
SER A 196
SER A 200
TRP A 407
PHE A 410
PHE A 411
TYR A 438
AQD  A1201 (-3.3A)
AQD  A1201 ( 3.9A)
AQD  A1201 (-2.8A)
AQD  A1201 (-3.6A)
None
AQD  A1201 (-4.7A)
AQD  A1201 (-4.6A)
None
0.81A32.39
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4AMJ_A_CVDA1359_1
(BETA-1 ADRENERGIC
RECEPTOR)		5wiv D(4) DOPAMINE
RECEPTOR, SOLUBLE
CYTOCHROME B562
CHIMERA
(Escherichia
coli;
Homo
sapiens)		5 / 12ASP A 115
VAL A 116
SER A 200
PHE A 410
PHE A 411
AQD  A1201 (-3.3A)
AQD  A1201 ( 3.9A)
AQD  A1201 (-3.6A)
AQD  A1201 (-4.7A)
AQD  A1201 (-4.6A)
1.50A32.39
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4AMJ_A_CVDA1359_1
(BETA-1 ADRENERGIC
RECEPTOR)		6bqh 5-HYDROXYTRYPTAMINE
RECEPTOR 2C,SOLUBLE
CYTOCHROME B562
(Escherichia
coli;
Homo
sapiens)		5 / 12TRP A 130
ASP A 134
SER A 219
ASN A 331
TYR A 358
None
E2J  A1201 (-3.0A)
E2J  A1201 (-3.2A)
None
None
1.31A14.29
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4AMJ_A_CVDA1359_1
(BETA-1 ADRENERGIC
RECEPTOR)		6bqh 5-HYDROXYTRYPTAMINE
RECEPTOR 2C,SOLUBLE
CYTOCHROME B562
(Escherichia
coli;
Homo
sapiens)		5 / 12TRP A 130
ASP A 134
SER A 219
TRP A 324
TYR A 358
None
E2J  A1201 (-3.0A)
E2J  A1201 (-3.2A)
E2J  A1201 ( 3.7A)
None
1.18A14.29
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4AMJ_A_CVDA1359_1
(BETA-1 ADRENERGIC
RECEPTOR)		6bqh 5-HYDROXYTRYPTAMINE
RECEPTOR 2C,SOLUBLE
CYTOCHROME B562
(Escherichia
coli;
Homo
sapiens)		7 / 12TRP A 130
ASP A 134
TRP A 324
PHE A 327
PHE A 328
ASN A 331
TYR A 358
None
E2J  A1201 (-3.0A)
E2J  A1201 ( 3.7A)
E2J  A1201 (-4.6A)
E2J  A1201 (-4.4A)
None
None
0.61A14.29
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4AMJ_A_CVDA1359_1
(BETA-1 ADRENERGIC
RECEPTOR)		6bqh 5-HYDROXYTRYPTAMINE
RECEPTOR 2C,SOLUBLE
CYTOCHROME B562
(Escherichia
coli;
Homo
sapiens)		7 / 12TRP A 130
ASP A 134
VAL A 135
TRP A 324
PHE A 327
PHE A 328
TYR A 358
None
E2J  A1201 (-3.0A)
E2J  A1201 (-3.8A)
E2J  A1201 ( 3.7A)
E2J  A1201 (-4.6A)
E2J  A1201 (-4.4A)
None
0.67A14.29
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4AMJ_A_CVDA1359_1
(BETA-1 ADRENERGIC
RECEPTOR)		6cm4 D(2) DOPAMINE
RECEPTOR, ENDOLYSIN
CHIMERA
(Escherichia
virus
T4;
Homo
sapiens)		7 / 12ASP A 114
VAL A 115
SER A 197
TRP A 386
PHE A 389
PHE A 390
TYR A 416
8NU  A2001 ( 3.0A)
8NU  A2001 ( 3.5A)
8NU  A2001 ( 3.6A)
8NU  A2001 ( 3.8A)
8NU  A2001 ( 4.5A)
8NU  A2001 ( 4.8A)
8NU  A2001 ( 4.9A)
0.71A18.01
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4AMJ_A_CVDA1359_1
(BETA-1 ADRENERGIC
RECEPTOR)		6g79 5-HYDROXYTRYPTAMINE
RECEPTOR 1B
(Homo
sapiens)		6 / 12TRP S 125
ASP S 129
SER S 212
PHE S 330
PHE S 331
TYR S 359
None
EP5  S 401 (-3.3A)
EP5  S 401 (-3.3A)
EP5  S 401 (-4.0A)
EP5  S 401 (-4.7A)
EP5  S 401 ( 4.9A)
1.17A14.22
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4AMJ_A_CVDA1359_1
(BETA-1 ADRENERGIC
RECEPTOR)		6g79 5-HYDROXYTRYPTAMINE
RECEPTOR 1B
(Homo
sapiens)		7 / 12TRP S 125
ASP S 129
SER S 212
TRP S 327
PHE S 330
PHE S 331
TYR S 359
None
EP5  S 401 (-3.3A)
EP5  S 401 (-3.3A)
None
EP5  S 401 (-4.0A)
EP5  S 401 (-4.7A)
EP5  S 401 ( 4.9A)
0.70A14.22
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4AMJ_B_CVDB1360_1
(BETA-1 ADRENERGIC
RECEPTOR)		3btz ALPHA-KETOGLUTARATE-
DEPENDENT
DIOXYGENASE ALKB
HOMOLOG 2
(Homo
sapiens)		5 / 12LEU A 218
VAL A 108
SER A 125
ASN A 159
TYR A 161
None
1.34A21.27
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4AMJ_B_CVDB1360_1
(BETA-1 ADRENERGIC
RECEPTOR)		3gdh TRIMETHYLGUANOSINE
SYNTHASE HOMOLOG
(Homo
sapiens)		5 / 12LEU A 817
VAL A 685
PHE A 761
PHE A 708
ASN A 704
None
None
None
None
SAH  A 854 (-4.0A)
1.38A20.68
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4AMJ_B_CVDB1360_1
(BETA-1 ADRENERGIC
RECEPTOR)		3pbl D(3) DOPAMINE
RECEPTOR, LYSOZYME
CHIMERA
(Escherichia
virus
T4;
Homo
sapiens)		8 / 12LEU A  89
ASP A 110
SER A 192
SER A 196
TRP A 342
PHE A 345
PHE A 346
TYR A 373
None
ETQ  A1200 (-3.5A)
ETQ  A1200 (-3.3A)
ETQ  A1200 ( 4.6A)
None
ETQ  A1200 (-4.4A)
ETQ  A1200 ( 4.5A)
ETQ  A1200 (-4.4A)
0.77A29.71
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4AMJ_B_CVDB1360_1
(BETA-1 ADRENERGIC
RECEPTOR)		3pbl D(3) DOPAMINE
RECEPTOR, LYSOZYME
CHIMERA
(Escherichia
virus
T4;
Homo
sapiens)		5 / 12LEU A  89
ASP A 110
SER A 196
PHE A 345
PHE A 346
None
ETQ  A1200 (-3.5A)
ETQ  A1200 ( 4.6A)
ETQ  A1200 (-4.4A)
ETQ  A1200 ( 4.5A)
1.40A29.71
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4AMJ_B_CVDB1360_1
(BETA-1 ADRENERGIC
RECEPTOR)		3pds FUSION PROTEIN
BETA-2 ADRENERGIC
RECEPTOR/LYSOZYME
(Escherichia
virus
T4;
Homo
sapiens)		5 / 12TRP A 109
ASP A 113
SER A 203
PHE A 290
TYR A 316
None
ERC  A1201 (-3.7A)
ERC  A1201 (-2.8A)
ERC  A1201 (-4.8A)
None
1.49A42.70
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4AMJ_B_CVDB1360_1
(BETA-1 ADRENERGIC
RECEPTOR)		3pds FUSION PROTEIN
BETA-2 ADRENERGIC
RECEPTOR/LYSOZYME
(Escherichia
virus
T4;
Homo
sapiens)		6 / 12TRP A 109
ASP A 113
SER A 207
PHE A 289
ASN A 312
TYR A 316
None
ERC  A1201 (-3.7A)
ERC  A1201 (-2.7A)
ERC  A1201 (-4.5A)
ERC  A1201 (-3.0A)
None
0.93A42.70
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4AMJ_B_CVDB1360_1
(BETA-1 ADRENERGIC
RECEPTOR)		3pds FUSION PROTEIN
BETA-2 ADRENERGIC
RECEPTOR/LYSOZYME
(Escherichia
virus
T4;
Homo
sapiens)		10 / 12TRP A 109
ASP A 113
VAL A 117
SER A 203
SER A 207
TRP A 286
PHE A 289
PHE A 290
ASN A 293
TYR A 316
None
ERC  A1201 (-3.7A)
None
ERC  A1201 (-2.8A)
ERC  A1201 (-2.7A)
None
ERC  A1201 (-4.5A)
ERC  A1201 (-4.8A)
ERC  A1201 (-3.5A)
None
0.73A42.70
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4AMJ_B_CVDB1360_1
(BETA-1 ADRENERGIC
RECEPTOR)		3pds FUSION PROTEIN
BETA-2 ADRENERGIC
RECEPTOR/LYSOZYME
(Escherichia
virus
T4;
Homo
sapiens)		10 / 12TRP A 109
ASP A 113
VAL A 117
SER A 203
TRP A 286
PHE A 289
PHE A 290
ASN A 293
ASN A 312
TYR A 316
None
ERC  A1201 (-3.7A)
None
ERC  A1201 (-2.8A)
None
ERC  A1201 (-4.5A)
ERC  A1201 (-4.8A)
ERC  A1201 (-3.5A)
ERC  A1201 (-3.0A)
None
0.69A42.70
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4AMJ_B_CVDB1360_1
(BETA-1 ADRENERGIC
RECEPTOR)		3pds FUSION PROTEIN
BETA-2 ADRENERGIC
RECEPTOR/LYSOZYME
(Escherichia
virus
T4;
Homo
sapiens)		5 / 12TRP A 109
ASP A 113
VAL A 117
SER A 204
TYR A 316
None
ERC  A1201 (-3.7A)
None
ERC  A1201 ( 4.1A)
None
1.36A42.70
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4AMJ_B_CVDB1360_1
(BETA-1 ADRENERGIC
RECEPTOR)		3pds FUSION PROTEIN
BETA-2 ADRENERGIC
RECEPTOR/LYSOZYME
(Escherichia
virus
T4;
Homo
sapiens)		5 / 12VAL A 114
PHE A 289
ASN A 293
ASN A 312
TYR A 316
ERC  A1201 (-3.8A)
ERC  A1201 (-4.5A)
ERC  A1201 (-3.5A)
ERC  A1201 (-3.0A)
None
1.19A42.70
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4AMJ_B_CVDB1360_1
(BETA-1 ADRENERGIC
RECEPTOR)		3rze HISTAMINE H1
RECEPTOR, LYSOZYME
CHIMERA
(Escherichia
virus
T4;
Homo
sapiens)		5 / 12TRP A 103
ASP A 107
TRP A 428
PHE A 432
TYR A 458
None
5EH  A1200 ( 2.6A)
5EH  A1200 ( 3.4A)
5EH  A1200 ( 4.3A)
5EH  A1200 ( 4.4A)
0.66A26.75
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4AMJ_B_CVDB1360_1
(BETA-1 ADRENERGIC
RECEPTOR)		4gbr BETA-2 ADRENERGIC
RECEPTOR
(Homo
sapiens)		11 / 12TRP A 109
ASP A 113
VAL A 117
SER A 203
SER A 207
TRP A 258
PHE A 261
PHE A 262
ASN A 265
ASN A 284
TYR A 288
None
CAU  A 500 (-3.0A)
CAU  A 500 (-4.2A)
CAU  A 500 (-3.3A)
CAU  A 500 (-4.1A)
None
CAU  A 500 (-4.2A)
CAU  A 500 (-4.6A)
CAU  A 500 (-3.4A)
CAU  A 500 (-3.3A)
CAU  A 500 (-4.6A)
0.51A58.02
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4AMJ_B_CVDB1360_1
(BETA-1 ADRENERGIC
RECEPTOR)		4ib4 CHIMERA PROTEIN OF
HUMAN
5-HYDROXYTRYPTAMINE
RECEPTOR 2B AND E.
COLI SOLUBLE
CYTOCHROME B562
(Escherichia
coli;
Homo
sapiens)		5 / 12TRP A 131
ASP A 135
SER A 222
TRP A 337
TYR A 370
None
ERM  A2001 (-3.2A)
ERM  A2001 ( 4.6A)
None
ERM  A2001 ( 4.8A)
1.38A28.44
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4AMJ_B_CVDB1360_1
(BETA-1 ADRENERGIC
RECEPTOR)		4ib4 CHIMERA PROTEIN OF
HUMAN
5-HYDROXYTRYPTAMINE
RECEPTOR 2B AND E.
COLI SOLUBLE
CYTOCHROME B562
(Escherichia
coli;
Homo
sapiens)		7 / 12TRP A 131
ASP A 135
TRP A 337
PHE A 340
PHE A 341
ASN A 344
TYR A 370
None
ERM  A2001 (-3.2A)
None
ERM  A2001 (-4.3A)
None
ERM  A2001 (-4.3A)
ERM  A2001 ( 4.8A)
0.65A28.44
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4AMJ_B_CVDB1360_1
(BETA-1 ADRENERGIC
RECEPTOR)		4lde LYSOZYME, BETA-2
ADRENERGIC RECEPTOR
(Escherichia
virus
T4;
Homo
sapiens)		5 / 12TRP A1109
ASP A1113
SER A1203
PHE A1290
TYR A1316
None
P0G  A1401 (-2.9A)
P0G  A1401 (-2.9A)
P0G  A1401 ( 4.9A)
None
1.26A42.33
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4AMJ_B_CVDB1360_1
(BETA-1 ADRENERGIC
RECEPTOR)		4lde LYSOZYME, BETA-2
ADRENERGIC RECEPTOR
(Escherichia
virus
T4;
Homo
sapiens)		8 / 12TRP A1109
ASP A1113
SER A1203
TRP A1286
PHE A1289
PHE A1290
ASN A1312
TYR A1316
None
P0G  A1401 (-2.9A)
P0G  A1401 (-2.9A)
None
P0G  A1401 ( 4.7A)
P0G  A1401 ( 4.9A)
P0G  A1401 (-2.9A)
None
0.79A42.33
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4AMJ_B_CVDB1360_1
(BETA-1 ADRENERGIC
RECEPTOR)		4lde LYSOZYME, BETA-2
ADRENERGIC RECEPTOR
(Escherichia
virus
T4;
Homo
sapiens)		5 / 12TRP A1109
ASP A1113
SER A1207
PHE A1289
ASN A1293
None
P0G  A1401 (-2.9A)
P0G  A1401 (-2.8A)
P0G  A1401 ( 4.7A)
P0G  A1401 (-3.0A)
1.29A42.33
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4AMJ_B_CVDB1360_1
(BETA-1 ADRENERGIC
RECEPTOR)		4lde LYSOZYME, BETA-2
ADRENERGIC RECEPTOR
(Escherichia
virus
T4;
Homo
sapiens)		8 / 12TRP A1109
ASP A1113
TRP A1286
PHE A1289
PHE A1290
ASN A1293
ASN A1312
TYR A1316
None
P0G  A1401 (-2.9A)
None
P0G  A1401 ( 4.7A)
P0G  A1401 ( 4.9A)
P0G  A1401 (-3.0A)
P0G  A1401 (-2.9A)
None
0.58A42.33
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4AMJ_B_CVDB1360_1
(BETA-1 ADRENERGIC
RECEPTOR)		4lde LYSOZYME, BETA-2
ADRENERGIC RECEPTOR
(Escherichia
virus
T4;
Homo
sapiens)		7 / 12TRP A1109
ASP A1113
VAL A1117
SER A1203
SER A1207
PHE A1289
PHE A1290
None
P0G  A1401 (-2.9A)
P0G  A1401 ( 4.4A)
P0G  A1401 (-2.9A)
P0G  A1401 (-2.8A)
P0G  A1401 ( 4.7A)
P0G  A1401 ( 4.9A)
0.92A42.33
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4AMJ_B_CVDB1360_1
(BETA-1 ADRENERGIC
RECEPTOR)		4lde LYSOZYME, BETA-2
ADRENERGIC RECEPTOR
(Escherichia
virus
T4;
Homo
sapiens)		8 / 12TRP A1109
ASP A1113
VAL A1117
SER A1203
TRP A1286
PHE A1289
PHE A1290
ASN A1312
None
P0G  A1401 (-2.9A)
P0G  A1401 ( 4.4A)
P0G  A1401 (-2.9A)
None
P0G  A1401 ( 4.7A)
P0G  A1401 ( 4.9A)
P0G  A1401 (-2.9A)
0.86A42.33
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4AMJ_B_CVDB1360_1
(BETA-1 ADRENERGIC
RECEPTOR)		4lde LYSOZYME, BETA-2
ADRENERGIC RECEPTOR
(Escherichia
virus
T4;
Homo
sapiens)		7 / 12TRP A1109
ASP A1113
VAL A1117
SER A1207
PHE A1289
PHE A1290
ASN A1293
None
P0G  A1401 (-2.9A)
P0G  A1401 ( 4.4A)
P0G  A1401 (-2.8A)
P0G  A1401 ( 4.7A)
P0G  A1401 ( 4.9A)
P0G  A1401 (-3.0A)
0.78A42.33
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4AMJ_B_CVDB1360_1
(BETA-1 ADRENERGIC
RECEPTOR)		4lde LYSOZYME, BETA-2
ADRENERGIC RECEPTOR
(Escherichia
virus
T4;
Homo
sapiens)		8 / 12TRP A1109
ASP A1113
VAL A1117
TRP A1286
PHE A1289
PHE A1290
ASN A1293
ASN A1312
None
P0G  A1401 (-2.9A)
P0G  A1401 ( 4.4A)
None
P0G  A1401 ( 4.7A)
P0G  A1401 ( 4.9A)
P0G  A1401 (-3.0A)
P0G  A1401 (-2.9A)
0.68A42.33
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4AMJ_B_CVDB1360_1
(BETA-1 ADRENERGIC
RECEPTOR)		4lde LYSOZYME, BETA-2
ADRENERGIC RECEPTOR
(Escherichia
virus
T4;
Homo
sapiens)		5 / 12VAL A1114
PHE A1289
ASN A1293
ASN A1312
TYR A1316
P0G  A1401 (-3.7A)
P0G  A1401 ( 4.7A)
P0G  A1401 (-3.0A)
P0G  A1401 (-2.9A)
None
1.35A42.33
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4AMJ_B_CVDB1360_1
(BETA-1 ADRENERGIC
RECEPTOR)		5v54 5-HYDROXYTRYPTAMINE
RECEPTOR 1B,OB-1
FUSED 5-HT1B
RECEPTOR,5-HYDROXYTR
YPTAMINE RECEPTOR 1B
(Homo
sapiens;
Spodoptera
frugiperda)		6 / 12TRP A 125
ASP A 129
SER A 212
PHE A 330
PHE A 331
TYR A 359
None
89F  A1201 (-3.3A)
89F  A1201 ( 3.8A)
89F  A1201 (-4.1A)
89F  A1201 (-4.6A)
None
1.31A14.48
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4AMJ_B_CVDB1360_1
(BETA-1 ADRENERGIC
RECEPTOR)		5v54 5-HYDROXYTRYPTAMINE
RECEPTOR 1B,OB-1
FUSED 5-HT1B
RECEPTOR,5-HYDROXYTR
YPTAMINE RECEPTOR 1B
(Homo
sapiens;
Spodoptera
frugiperda)		7 / 12TRP A 125
ASP A 129
SER A 212
TRP A 327
PHE A 330
PHE A 331
TYR A 359
None
89F  A1201 (-3.3A)
89F  A1201 ( 3.8A)
89F  A1201 (-3.6A)
89F  A1201 (-4.1A)
89F  A1201 (-4.6A)
None
0.81A14.48
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4AMJ_B_CVDB1360_1
(BETA-1 ADRENERGIC
RECEPTOR)		5wiv D(4) DOPAMINE
RECEPTOR, SOLUBLE
CYTOCHROME B562
CHIMERA
(Escherichia
coli;
Homo
sapiens)		7 / 12ASP A 115
SER A 196
SER A 200
TRP A 407
PHE A 410
PHE A 411
TYR A 438
AQD  A1201 (-3.3A)
AQD  A1201 (-2.8A)
AQD  A1201 (-3.6A)
None
AQD  A1201 (-4.7A)
AQD  A1201 (-4.6A)
None
0.80A32.39
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4AMJ_B_CVDB1360_1
(BETA-1 ADRENERGIC
RECEPTOR)		6bqh 5-HYDROXYTRYPTAMINE
RECEPTOR 2C,SOLUBLE
CYTOCHROME B562
(Escherichia
coli;
Homo
sapiens)		5 / 12TRP A 130
ASP A 134
SER A 219
ASN A 331
TYR A 358
None
E2J  A1201 (-3.0A)
E2J  A1201 (-3.2A)
None
None
1.33A14.29
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4AMJ_B_CVDB1360_1
(BETA-1 ADRENERGIC
RECEPTOR)		6bqh 5-HYDROXYTRYPTAMINE
RECEPTOR 2C,SOLUBLE
CYTOCHROME B562
(Escherichia
coli;
Homo
sapiens)		6 / 12TRP A 130
ASP A 134
SER A 219
TRP A 324
PHE A 328
TYR A 358
None
E2J  A1201 (-3.0A)
E2J  A1201 (-3.2A)
E2J  A1201 ( 3.7A)
E2J  A1201 (-4.4A)
None
1.39A14.29
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4AMJ_B_CVDB1360_1
(BETA-1 ADRENERGIC
RECEPTOR)		6bqh 5-HYDROXYTRYPTAMINE
RECEPTOR 2C,SOLUBLE
CYTOCHROME B562
(Escherichia
coli;
Homo
sapiens)		7 / 12TRP A 130
ASP A 134
TRP A 324
PHE A 327
PHE A 328
ASN A 331
TYR A 358
None
E2J  A1201 (-3.0A)
E2J  A1201 ( 3.7A)
E2J  A1201 (-4.6A)
E2J  A1201 (-4.4A)
None
None
0.63A14.29
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4AMJ_B_CVDB1360_1
(BETA-1 ADRENERGIC
RECEPTOR)		6cm4 D(2) DOPAMINE
RECEPTOR, ENDOLYSIN
CHIMERA
(Escherichia
virus
T4;
Homo
sapiens)		7 / 12LEU A  94
ASP A 114
SER A 197
TRP A 386
PHE A 389
PHE A 390
TYR A 416
None
8NU  A2001 ( 3.0A)
8NU  A2001 ( 3.6A)
8NU  A2001 ( 3.8A)
8NU  A2001 ( 4.5A)
8NU  A2001 ( 4.8A)
8NU  A2001 ( 4.9A)
0.81A18.01
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4AMJ_B_CVDB1360_1
(BETA-1 ADRENERGIC
RECEPTOR)		6g79 5-HYDROXYTRYPTAMINE
RECEPTOR 1B
(Homo
sapiens)		6 / 12TRP S 125
ASP S 129
SER S 212
PHE S 330
PHE S 331
TYR S 359
None
EP5  S 401 (-3.3A)
EP5  S 401 (-3.3A)
EP5  S 401 (-4.0A)
EP5  S 401 (-4.7A)
EP5  S 401 ( 4.9A)
1.16A14.22
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4AMJ_B_CVDB1360_1
(BETA-1 ADRENERGIC
RECEPTOR)		6g79 5-HYDROXYTRYPTAMINE
RECEPTOR 1B
(Homo
sapiens)		7 / 12TRP S 125
ASP S 129
SER S 212
TRP S 327
PHE S 330
PHE S 331
TYR S 359
None
EP5  S 401 (-3.3A)
EP5  S 401 (-3.3A)
None
EP5  S 401 (-4.0A)
EP5  S 401 (-4.7A)
EP5  S 401 ( 4.9A)
0.68A14.22
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4AMJ_B_CVDB1360_2
(BETA-1 ADRENERGIC
RECEPTOR)		3pds FUSION PROTEIN
BETA-2 ADRENERGIC
RECEPTOR/LYSOZYME
(Escherichia
virus
T4;
Homo
sapiens)		4 / 4VAL A 114
ASP A 192
TYR A 199
TRP A 313
ERC  A1201 (-3.8A)
ERC  A1201 (-4.2A)
None
ERC  A1201 (-4.4A)
0.47A42.70
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4AMJ_B_CVDB1360_2
(BETA-1 ADRENERGIC
RECEPTOR)		4gbr BETA-2 ADRENERGIC
RECEPTOR
(Homo
sapiens)		4 / 4VAL A 114
ASP A 192
TYR A 199
TRP A 285
CAU  A 500 (-3.5A)
None
None
None
0.52A58.02
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4AMJ_B_CVDB1360_2
(BETA-1 ADRENERGIC
RECEPTOR)		4lde LYSOZYME, BETA-2
ADRENERGIC RECEPTOR
(Escherichia
virus
T4;
Homo
sapiens)		4 / 4VAL A1114
ASP A1192
TYR A1199
TRP A1313
P0G  A1401 (-3.7A)
None
None
1WV  A1403 ( 4.3A)
0.97A42.33